We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Pepsinogen Validated for Atrophic Gastritis Diagnosis

By LabMedica International staff writers
Posted on 01 Aug 2017
Print article
Image: The Assure H. Pylori Rapid Test is an immunochromatographic test for diagnosing infection from H. pylori in patients with gastric disorders (Photo courtesy of MP Biomedicals).
Image: The Assure H. Pylori Rapid Test is an immunochromatographic test for diagnosing infection from H. pylori in patients with gastric disorders (Photo courtesy of MP Biomedicals).
Atrophic gastritis (AG) and intestinal metaplasia (IM) are well-recognized as high-risk conditions for developing gastric cancer (GC), and both have been identified as the precancerous lesions, but the clinical symptoms of AG are not specific.

The early detection of precancerous lesions of GC in general population and following up with the condition are important considerations for reducing mortality, increasing survival rates, and improving quality of life. The measurement of pepsinogen (PG) as a screening test for chronic atrophic gastritis (AG) in health check-up populations has been suggested.

Physicians at the Second Affiliated Hospital of Zhejiang University (Hangzhou, China) enrolled subjects, who received consecutive regular health check-up from January 2014 to June 2015. The patients included in this study ranged from 20 to 70 years in age. All the participants underwent gastroendoscopy and pathology tests, serum PG test, 13C–urea breath test or Helicobacter pylori (Hp) serological current infection marker rapid test in one day.

Serum PG levels were assayed by chemiluminescent microparticle immunoassay method using Abbott ARCHITECT Pepsinogen I and II Reagent Kit. Each subject was also examined with 13C–urea breath test or Hp serological current infection marker rapid test. Hp infection was determined based on the results of 13C–urea breath test or H. pylori serological rapid current infection marker test, combined with the pathological screening.

The scientists found the total Hp infection rate was 40% and based on pathology, the 996 participants were divided into three groups: non-atrophic (NAG), mild-moderate atrophic (MAG), and severe atrophic (SAG). Compared with NAG and MAG groups, the Pepsinogen I (PGI)/ Pepsinogen II (PGII) ratio (PGR) decreased significantly in SAG group. PGI and PGII levels were significantly elevated in Hp-positive group, while the PGR was markedly decreased. When MAG and SAG groups were combined and compared with NAG group, the best cutoff value for atrophy diagnosis was PGI ≤50.3 ng/mL; the cutoff value in Hp-negative group was absolutely higher than in Hp-positive group. When NAG and MAG groups were combined and compared with the SAG group, the best cutoff value for diagnosis of severe atrophy was at PGR ≤4.28. The cutoff values in Hp-negative and Hp-positive groups were calculated at PGR ≤6.28 and ≤4.28, respectively.

The authors concluded that serum pepsinogens are a cost effective screening method in the identification of patients with AG, especially severe AG, which are precancerous lesions of GC. The use of different cutoff values of PG for Hp-negative and Hp-positive groups may offer greater efficacy in the diagnosis of AG. The study was published on July 20, 2017, in the journal BMC Gastroenterology.

Related Links:
Second Affiliated Hospital of Zhejiang University

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.